| Sep 3 |
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
|
| Aug 18 |
Cyclacel Pharmaceuticals Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Aug 15 |
Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript
|
| Aug 14 |
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates
|
| Aug 14 |
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
|
| Aug 7 |
Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
|
| Jul 25 |
Cyclacel Pharmaceuticals (CYCC) Upgraded to Strong Buy: Here's What You Should Know
|
| Jun 26 |
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
|
| Jun 6 |
All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy
|
| Jun 4 |
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
|
